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A high proliferation rate predicts a poor prognosis in many types
of malignancies. Several methods are available for assessing
proliferation in human tumours (Keshgegian and Cnaan, 1995).
The two most common methods used in recent years have been
flow cytometric measurement of the S-phase fraction (SPF) and
immunohistochemical staining of the proliferation antigen Ki-67.
The Ki-67 antigen is expressed over the whole active cell cycle
phases from G1 to M (Gerdes et al, 1991).
Many studies indicate that in breast cancer proliferation activity
measured by either Ki-67 antibody or by flow cytometric SPF has
prognostic value (Joensuu et al, 1990; Sigurdsson et al, 1990;
Weikel et al, 1991, 1995; Railo et al, 1993; Veronese et al, 1993;
Camplejohn et al, 1995; Dettmar et al, 1997; Molino et al, 1997).
Few studies, however, have compared the prognostic value of
these two methods. The results of such studies have been variable
as regards breast cancer (Gasparini et al, 1994; Keshgegian and
Cnaan, 1995; Pierga et al, 1996; Dettmar et al, 1997). In a recent
extensive study, Ki-67 was found to be a stronger prognostic factor
than SPF (Railo et al, 1997).
Several studies on soft-tissue sarcomas (STS) have shown that a
high expression of Ki-67 predicts an adverse prognosis. Most of
these studies are based on a limited number of cases, and few have
included more than 100 patients (Choong et al, 1994; Drobnjak et
al, 1994; Rudolph et al, 1997).
We have found previously that a high SPF was associated with
poor survival in patients whose primary tumour was diploid. SPF
did not predict survival in patients with non-diploid tumours
(Huuhtanen et al, 1996). Other studies on the prognostic value of
SPF have been inconsistent, although two recent large studies
suggest that SPF has prognostic value irrespective of ploidy when
a low cut-point value of 3% or 4% is used (Collin et al, 1997;
Gustafson et al, 1997).
The aim of this study was to evaluate the prognostic value of
Ki-67 in STS and to compare it with SPF.
PATIENTS AND METHODS
Patients
The patients were consecutive adult patients treated for STS of the
limbs or superficial trunk by the soft-tissue sarcoma group at
Helsinki University Central Hospital between January 1987 and
May 1993. They were treated according to the guidelines of the
Helsinki STS group (Wiklund et al, 1996). In the present prog-
nostic study, we included patients with primary tumour and SPF
determined in the context of our previous study, with the exception
of patients with dermatofibrosarcoma protuberans (Huuhtanen et
al, 1996).
The number of patients was 145. Formalin-fixed, paraffin-
embedded histological samples were available for immunohisto-
chemical staining in 135 cases. In 12 cases, the Ki-67 staining was
repeatedly unsuccessful, probably because of inappropriate
sample fixation. Histopathological subtypes and grades of the
missing samples, and the samples with unsuccessful Ki-67
staining are shown in Table 1.
Altogether 123 patients were finally included in this study. One
patient had a tumour which was limited to the skin only. Thirty-
eight tumours were subcutaneous, or both subcutaneous and cuta-
neous. In 82 cases, the primary tumour was located deep within
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pretreatment characteristics of the patients in this study are shown
in Table 2.
The Helsinki STS group is a member of the Scandinavian
Sarcoma Group (SSG), in which a four-grade histological malig-
nancy grading system is applied. For the grading, the combination
of the histological type and a combination of histopathological
parameters, which include necrosis, vascular invasion, cellularity,
mitotic activity and nuclear pleomorphism, is used. Since the
publication of our study on SPF (Huuhtanen et al, 1996), the
histopathological subtypes have been changed in seven cases
during the peer review sessions by the SSG pathologists.
The median follow-up time of living patients (n = 71) was 72
months (range 22–447 months). Four patients have died without
disease. Fifty-one patients developed metastasis, nine of them are
living.
In the statistical analysis, we stratified the cases according to
genetic classification. We separated tumours known to have
common specific chromosomal changes, e.g. synovial sarcomas,
extraskeletal Ewing’s sarcoma, myxoid liposarcoma and round
cell liposarcoma. The remaining cases formed a mixed group, of
which the largest proportion were pleomorphic sarcomas. Table 2
shows the stratification. Three sarcomas with specific chromo-
somal changes were included in the miscellaneous sarcoma group
because they were single cases of alveolar rhabdomyosarcoma,
extraskeletal myxoid chondrosarcoma and clear cell sarcoma
(Fletcher, 1995; Sheer, 1997).
Methods
Several different antibodies detect the same large nuclear active
phase protein (Ki-67 antigen). In this study, we used the mono-
clonal Mib-1 antibody, which reacts with Ki-67 in formalin-fixed
archival material.
The samples were deparaffinated in xylene and rehydrated in
alcohol to distilled water. Antigen demasking was carried out by
heating the samples in a microwave oven (850 W) in citric acid
buffer (pH 6, 0.1 M) four times for 5 min. Metanol peroxidase
(1.6%) was used to inhibit the endogenous peroxidase activity of
the sample. Ki-67 staining was carried out by mouse anti-human
monoclonal Mib-1 antibody (PharMingen). Our antibody dilution
was 1:500, and we incubated samples overnight at room tempera-
ture. To reveal the binding of the primary antibody by peroxidase
staining, we used the Vectastain ABC kit (Vector Laboratories).
Haematoxylin was used for background staining.
When evaluating the results of the immunostaining, we chose
the tumour area with the highest density of positive nuclear
staining. A magnification of 10 ´ 40 was used. The percentage of
positively stained nuclei was evaluated with an ocular grid of 100
(10 ´ 10) squares. We counted all the positive nuclei from this
area. To estimate the negative nuclei in the same area of 100
squares, we counted three different rows of ten squares and multi-
plied the mean of the results by ten. The percentage of positive
nuclei was counted by dividing the positive stained cells by the
entire number of cells in the same area. In the case of tumours with
scarce cellularity, several fields were evaluated, and negative
nuclei were counted from the whole grid area of 100 squares. All
samples were scored by two independent observers (RH and TB).
When the interobserver difference in the result was greater than
5%, the sample was rescored by the two investigators together.
A modification of the basic Hedley method was used in flow
cytometric measurements (Hedley, 1989; Heiden et al, 1991). The
sections (100 mm) from the paraffin blocks were placed in fine-
mesh bags which were inserted into cassettes and then dewaxed
and rehydrated in a tissue processor. Enzymatic digestion was
carried out with Subtilisin Carlsberg (Sigma Protease type 24) and
all centrifugation steps were omitted, resulting in nuclei suspen-
sions with extremely low amounts of clumped nuclei and debris.
The nuclei were stained with DAPI (final concentration 5 mM) and
analysed using a PAS 2 flow cytometer. To confirm the ploidy of
near-diploid populations, the DNA content of the identified nuclei
was measured by means of a static image analysis system.
Tumours were considered diploid if only one G1 peak was present.
For determination of the DNA index in grossly aneuploid cell
populations, the first peak to the left was assumed to represent
diploid cells. For the determination of the percentage of cells in the
S-phase of the cell cycle, the MultiCycle program with the sliced-
nuclei option for background subtraction, developed by
Rabinowich, was used (Phoenix Flow System, San Diego, CA,
USA). Flow cytometry measurements were carried out at the
Radiobiological Department of the Karolinska Institute in
Stockholm (Huuhtanen et al, 1996).
Statistical methods
Survival analyses were carried out with the Macintosh SPSS
computer program, and all other analyses with the Macintosh
Statistica program. The correlations between different variables,
except ploidy, were calculated with the Spearman rank order
correlation test. The confidence intervals of the Spearman rank
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Table 1 Histology and grade of the missing samples and the unsuccessful Ki-67 stainings
Histology Missing samples, n Unsuccessful staining, n
Malignant fibrous histiocytoma 4 (G3 = 3, G4 = 1)a 1 (G4 = 1)
Leiomyosarcoma 2 (G1 = 1, G3 = 1) 4 (G1 = 1, G3 = 2, G4 = 1)
Synovial sarcoma 1 (G3 = 1) 1 (G3 = 1)
Extraskeletal Ewing’s sarcoma 2 (G4 = 2)
Epithelioid sarcoma 1 (G3 = 1)
Liposarcoma 2 (G1 = 2)
Extraskeletal osteosarcoma 2 (G3 = 1, G4 = 1)
Unclassified sarcoma 1 (G4 = 1)
Fibrosarcoma 1 (G1 = 1)
aG1–G4 = number of patients with grade 1–4 tumours.order correlation test were calculated according to Altman (1994).
The correlation between ploidy and Ki-67 was calculated with the
Mann–Whitney U-test.
Analyses of disease-specific overall survival (DSOS) and
metastasis-free survival (MFS) were carried out using the Cox
regression model. In the Cox regression model analysis, Ki-67 and
SPF were continuous variables. The prognostic value of the
different cut-off points of Ki-67 and SPF was further investigated
by dividing the material into two by 10% percentiles (i.e. cut-off
points defining 10% of the patients in the low-risk and 90% in the
high-risk group, 20% in the low-risk and 80% in the high-risk
group, etc.). The corresponding cut-off values for Ki-67 and SPF
are shown in Figure 1. For each cut-off point, the relative risk of
death or distant relapse and 95% confidence levels were calculated
by Cox regression analysis.
Survival curves were calculated by using the cut-point value of
10% for Ki-67, the value with the greatest discriminative power in
the study of Choong et al (1994). Thirty-four (28%) patients had
tumours with equal or lower Ki-67 value than 10%. In the group of
miscellaneous sarcomas, 18 (19%) tumours of 94 cases were
below this limit. To compare the results with SPF, we chose the
cut-off point of 3.9% for SPF, which divided the material similarly
to the Ki-67 cut-off point of 10% (i.e. 28% had equal or lower
values of SPF). The survival curves have been calculated by the
Kaplan–Meier method (Figures 2 and 3).
RESULTS
The median value of Ki-67 was 18% (range 1–55%). The median
of Ki-67 was highest in malignant fibrous histiocytomas and lowest
in liposarcomas. Low-grade tumours had a lower median of Ki-67
than high-grade tumours. The medians and ranges of Ki-67 and
SPF by grade, histotype and genetic class are shown in Table 3.
The Ki-67 staining score was strongly correlated with histolog-
ical grade (P < 0.001), ploidy (P < 0.001) and SPF [rs (±95%CI) =
0.57 (0.44–0.68), P < 0.001]. There was no correlation between
Ki-67 and tumour size (P = 0.2), or SPF and size (P = 0.16). SPF
correlated with grade and ploidy (P < 0.001 both). The correlations
between Ki-67 and SPF are shown in Figure 4, with diploid and
non-diploid tumours presented separately.
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Table 2 Pretreatment characteristics
Characteristic n %
Sex
Female 66 54
Male 57 46
Age
Median (range), years 53 (16–89)
WHO performance status
09 0 7 3
12 0 1 6
27 6
34 3
Unknown 2 2
Location
Trunk 26 21
Limb 97 79
Site
Only cutaneous/subcutaneous 39 32
Deep 82 67
Unknown 2 2
Size
<5 cm 34 28
³5c m 8 6 7 0
Unknown 3 2
Ploidy
Diploid 59 48
Non-diploid 64 52
Grade
I6 5
II 26 21
III 49 40
IV 42 34
Histology
Malignant fibrous histiocytomaa (G2 = 4, G3 = 14, G4 = 16)b 34 28
Liposarcomac (G1 = 2, G2 = 8, G3 = 2, G4 = 3) 15 12
Leiomyosarcoma (G1 = 2, G2 = 2, G3 = 5, G4 = 2) 11 9
Synovial sarcoma (G2 = 1, G3 = 9, G4 = 2) 12 10
Extraskeletal Ewing’s sarcoma (G3 = 1, G4 = 7) 8 6
Fibrosarcoma (G1 = 1, G2 = 4, G3 = 2) 7 6
Malignant Schwannoma (G2 = 1, G3 = 2, G4 = 2) 5 4
Unclassified sarcoma (G1 = 1, G2 = 2, G3 = 8, G4 = 8) 19 15
Other sarcomad (G2 = 4, G3 = 3, G4 = 3) 12 10
Histological grouping by known chromosomal changes n (diploid n)
Miscellaneous sarcoma 94 (34) 76
Synovial sarcoma 12 (11) 10
Myxoid liposarcoma and round cell liposarcoma 9 (7) 7
Extraskeletal Ewing’s sarcoma 8 (7) 7
aStoriform–pleomorphic n = 27, myxoid n = 7; bG1–G4 = number of patients
with grade 1–4 tumours; cwell-differentiated n = 2, myxoid n = 8, round cell
n = 1, pleomorphic n = 3, pleomorphic–storiform n = 1; dmyxofibrosarcoma
n = 1, extraskeletal myxoid chondrosarcoma n = 1, clear cell sarcoma n = 1,
alveolar rhabdomyosarcoma n = 1, malignant haemangiopericytoma n = 1,
stromal sarcoma n = 1, angiosarcoma n = 2, epithelioid sarcoma n = 2,
extraskeletal osteosarcoma n = 2.
Table 3 Medians and ranges of Ki-67 and SPF of 123 tumours divided by
histotype, grade and by genetic class
Histotype n Ki-67 median (%) SPF median (%)
(range) (range)
Malignant fibrous histiocytoma 34 26 (5.5–55) 11.6 (0–38.2)
Liposarcoma 15 4 (1–40) 4.9 (0.9–24.3)
Leiomyosarcoma 11 11 (5–35.5) 10.3 (1–29.2)
Synovial sarcoma 12 9.3 (3.5–20) 4.0 (1.8–8.3)
Extraskeletal Ewing’s sarcoma 8 21  (7.5–44) 9.3 (3.2–21.9)
Malignant schwannoma 5 19 (9–34) 6 (1.9–16.3)
Fibrosarcoma 7 11.5 (3.5–34) 4 (1–16.3)
Unclassified 19 22 (8–48 11.2 (3.3–24.9)
Other 12 18 (2–48) 6.6 (1.7–15.3)
Grade (n)
1 6 6.5 (1–21) 4.9 (1–24.2)
2 26 11  (2–48) 3.7 (0.9–18.5)
3 49 18 (3–43) 8.3 (0–29.5)
4 42 28 (7.5–55) 12.1 (1.2–38.2)
Histological grouping by known
chromosomal changes
Miscellaneous 94 20.5 (1–55) 9.7 (0–38.2)
Synovial sarcoma 12 9.3 (3.5–20) 4 (1.8–8.3)
Liposarcoma 9 4 (2–32) 2.4 (0.9–10.2)
Extraskeletal Ewing’s sarcoma 8 21 (7.5–35.5) 9.25 (3.2–21.9)When analysed as a continuous variable, Ki-67 was a stronger
predictor of both MFS and DSOS (P = 0.003 and P = 0.04 respec-
tively) than SPF (P = 0.06 and 0.07 respectively). When using cut-
off points of 10% for Ki-67, it predicted MFS and DSOS (P = 0.02
and P = 0.02 respectively). When using a cut-off point of 3.9% for
SPF, it predicted MFS and DSOS (P = 0.03 and P = 0.003 respec-
tively). The estimated 5 years of MFS was 79% for tumours with
Ki-67 ≤ 10% and 57% for tumours with Ki-67 > 10%. The esti-
mated 5 years of DSOS was 82% for tumours with Ki-6 ≤ 10%
and 60% for tumours with Ki-67 > 10%. The estimated 5 years of
MFS was 81% for tumours with SPF ≤ 3.9% and 57% for tumours
with SPF > 3.9%. The estimated 5 years of DSOS was 90% for
tumours with SPF ≤ 3.9% and 57% for tumours with SPF > 3.9%.
But when analysed separately in diploid and non-diploid tumour
948 RL Huuhtanen et al
British Journal of Cancer (1999) 79(5/6), 945–951 © Cancer Research Campaign 1999
10
1
0.1 0.1
10
1
0
4.5
8
11
14
18
21
26
31
35.5
0
4.5
8
11
14
18
21
26
31
35.5
10
1
0.1
10
1
0.1
2
3.1
4
5.6
7.5
10.2
12.8
16.3
21.9
SPF
2
3.1
4
5.6
7.5
10.2
12.8
16.3
21.9
SPF
Ki-67 Ki-67
R
e
l
a
t
i
v
e
 
r
i
s
k
 
o
f
 
d
e
a
t
h
R
e
l
a
t
i
v
e
 
r
i
s
k
 
o
f
 
d
e
a
t
h
R
e
l
a
t
i
v
e
 
r
i
s
k
 
o
f
 
m
e
t
a
s
t
a
s
i
s
R
e
l
a
t
i
v
e
 
r
i
s
k
 
o
f
 
m
e
t
a
s
t
a
s
i
s
A
CD
B
Figure 1 Relative risks of metastases and death according to different cut-points of Ki-67 and SPF. 95% confidence intervals indicated by crossbars.
(A) Metastasis-free survival (MFS) by Ki-67; (B) disease-free overall survival (DSOS) by Ki-67; (C) MFS by SPF; (D) DSOS by SPF
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Figure 2 Metastasis-free survival (MFS) in different genetic classes. Bold line Ki-67 ≤10%, fine line Ki-67 > 10%groups, SPF cut-point of 3.9 predicted DSOS only in diploid
tumours and not in non-diploid tumours (P = 0.02 and P = 0.02
respectively). MFS and DSOS in the four genetic groups,
according to the cut-off points of 10% for Ki-67 and 3.9% for the
SPF, are shown in Figures 2 and 3. Analysed in this way, Ki-67
was of significant prognostic value only in the group of miscella-
neous sarcomas (P-value for MFS <0.001 and P-value for DSOS
= 0.01). Figure 4 gives the discriminative values of Ki-67 and SPF
for MFS and DSOS as a function of various cut-off points by rela-
tive risk and confidence interval.
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Table 4 Ki-67 antigen expression and prognosis in STS
Reference n Histology Antibody OSa P-value Cut-off
point (%)
Zehr et al (1990) 29 MFHb Ki-67 0.43
Ueda et al (1989) 34 Mixed Ki-67 <0.005
Drobnjak et al (1994) 172 Mixed Ki-67 0.03 20
Choong et al (1994) 182 Mixed Mib-1 0.0001 10
Yang et al (1995) 54 MFHb Mib-1 0.00008 25
Levine et al (1997) 52 Mixed Ki-67 0.0019 40
Rudolph et al (1997) 126 Mixed Ki-S11 0.0004 20
125 Ki-S1 0.0008
Huuhtanen et al (1998) 123 Mixed Mib-1 0.02c 10
aOS, overall survival; bMFH, malignant fibrous histiocytoma; cDSOS disease-specific overall survival.
Figure 3 Disease-specific overall survival (DSOS) in different genetic classes. Bold line Ki-67 ≤ %, fine line Ki-67 > 10%
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Figure 4 Correlations between Ki-67 and SPF. Diploid and non-diploid tumours are represented separatelyDISCUSSION
The results of our study are in accordance with previous findings
(Table 4), which indicate that Ki-67 is of prognostic value in STS.
Compared with SPF, Ki-67 seemed to be a stronger prognostic
factor. Ki-67 measurements are also more economical and easier
to perform than SPF measurements. When comparing the discrim-
inative values of different cut-off points, it became evident that the
weaker prognostic effect of SPF seems to be due to the poor
discriminative power of high SPF values.
With low cut-off points, SPF seemed to be an equally effective
prognostic factor as Ki-67, which is in accordance with previous
results (Collin et al, 1997; Gustafson et al, 1997). The results of
Gustafson and of Collin are not directly comparable to ours,
however, because both of these investigators excluded 35–37% of
their tumours because of uninterpretable histograms. The majority
of the excluded cases were non-diploid. Because of differences in
techniques, we were able to calculate the SPF also in the majority
of cases with non-diploid tumours. These histograms, neverthe-
less, did not add much to the prognostic value of SPF because SPF
failed to be of prognostic value in non-diploid tumours, as shown
previously (Huuhtanen et al, 1996).
Thus, in contrast to SPF, our results indicate that Ki-67 can be
utilized to define a small group of patients with a high risk of
relapse, whereas SPF and Ki-67 seemed equivalent in their ability
to define a low-risk group. We can only speculate about why the
highest SPF values fail to have prognostic implication. Because
the SPF is a static rather than a dynamic proliferation parameter, a
high value is not necessarily the result of a high proportion of
cycling cells. A prolonged duration of the SPF, for example due to
a highly disorganized genome, will also result in a high SPF. Our
previously published result, i.e. that SPF is a statistically signifi-
cant prognostic variable in diploid but not in non-diploid
sarcomas, could thus support this hypothesis.
One difficulty in trying to find prognostic indicators for STS is the
extreme heterogeneity of this group of tumours. Although many
similarities in behaviour between different histotypes can be found,
for example the propensity to blood-borne metastasis vs. lymphatic
spread and the tendency to respect anatomical barriers in their
growth, many entities still have distinct features. Especially sarcomas
characterized by a specific pathognomonic gene translocation such
as synovial sarcoma, Ewing’s sarcoma, mesenchymal chondro-
sarcoma and myxoid liposarcoma often display specific behaviour.
Features distinguishing these entities from other STS include
frequent late relapse in synovial sarcoma, myxoid liposarcoma and
Ewing’s sarcoma, soft-tissue metastases in myxoid liposarcoma and
bone metastases in Ewing’s sarcoma (Enzinger and Weiss, 1995).
In this study, we therefore decided to stratify the cases with
respect to histogenesis, with special reference to disease-specific
chromosomal translocations. When we analysed the prognostic
value of proliferation measured by Ki-67 in these subgroups, it
appeared that the discriminative power is quite strong in the mixed
group of miscellaneous, mostly pleomorphic sarcomas. There was
no clear indication of prognostic value in any of the tumours char-
acterized by specific gene translocations because these tumour
groups were too small to be analysed separately. Probably, the
unexpected result in the synovial sarcoma patient group, in which
low proliferative activity correlated with poorer outcome, is
simply coincidental. In the group of miscellaneous pleomorphic
sarcomas, however, the results seem sufficiently promising to
justify a large confirmatory study.
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